Richardson, MD, detailed the strategic integration of mezigdomide into several areas including the unmet need of post CAR ...
Dr. Gabriel Mannis from Stanford University and Dr. Gail Roboz from Weill Cornell Medicine discussed the evolving treatment ...
Phase 2b data show RAD101 amino acid PET hits 90% concordance, helping distinguish brain metastasis recurrence from ...
When contextualized with the developments across all genitourinary [GU] malignancies, especially renal cell carcinoma and ...
Menin inhibitors reshape AML care, boosting targeted options for KMT2A- and NPM1-mutant disease, with promising frontline ...
An exploratory analysis of the phase 2 ALYCANTE trial (NCT04531046) reveals that patients with relapsed/refractory large ...
Experts review a stage IV NSCLC case, debating whether to delay treatment while awaiting PD-L1 results to ensure a more ...
FDA fast track designation applies to ALK+ NSCLC progressing after ≥2 ALK TKIs, reflecting limited post-lorlatinib ...
Theriva Biologics has received FDA agreement on the core design elements of a pivotal phase 3 trial evaluating zabilugene ...
Top-line findings from the ICESECRET clinical trial (NCT02399124) featuring the ProSense Cryoablation System for the ...
Frontline gastric/GE junction cancer care now pairs chemo with checkpoint inhibitors for PD-L1 CPS≥1, improving survival and ...
Regulatory review timelines shifted from March 29 to June 29, 2026, after FDA requested more time to assess CMC/manufacturing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results